Human Pharma Research & Development Approach Human Pharma Research & Development Approach Human Pharma Research & Development Approach
Inauguration of new integrated Asian Veterinary R&D Center in China Inauguration of new integrated Asian Veterinary R&D Center in China Boehringer Ingelheim confirms its commitment to growth in China with the investment of 19 million euros in its new integrated Asian Veterinary Research & Development Center
Immunology Respiratory Research Immunology Respiratory Research Find out more about our research and development in Immunology & Respiratory diseases
New exchange platform with Harbin Research Institute New exchange platform with Harbin Research Institute Boehringer Ingelheim and Harbin Veterinary Research Institute set up ‘industry-academia-research’ exchange platform
Oncology and Cancer Immunology Research Oncology and Cancer Immunology Research Find out more about our research and development in oncology and cancer immunology.
Largest European development center for biotechnology Largest European development center for biotechnology Boehringer Ingelheim inaugurates largest European development center for biotechnology
2020 European PRRS Research Award sponsorship 2020 European PRRS Research Award sponsorship 2020 European PRRS Research Award: Boehringer Ingelheim calls for submissions
BI Focuses COVID-19 Clinical Research on Alteplase BI Focuses COVID-19 Clinical Research on Alteplase BI focuses its COVID-19 therapy research on the development of alteplase as a potential treatment for COVID-19 patients with severe breathing problems
BI increases commitments to sustainable development BI increases commitments to sustainable development At the World Health Summit 2021, Boehringer Ingelheim announces updates to its strategic approach to sustainable development
Boehringer expands cancer research at Vienna site Boehringer expands cancer research at Vienna site Boehringer Ingelheim expands cancer research at its Vienna site
2021 PRRS Research Award winners announced 2021 PRRS Research Award winners announced The 2021 European PRRS Research Award winners announced
Winners of the 2020 European PRRS Research Award Winners of the 2020 European PRRS Research Award Winners of the 2020 European PRRS Research Award announced Three winner awarded 25,000 euro each for their research.
Winners of the 2019 European PRRS Research Award Winners of the 2019 European PRRS Research Award Winners of the 2019 European PRRS Research Award announced.
Research ruminant animal health well-being Research ruminant animal health well-being Boehringer Ingelheim supports young scientists and veterinarians dedicated to ruminant health research
Boehringer Ingelheim Advances Oncology Research Boehringer Ingelheim Advances Oncology Research Boehringer Ingelheim Advances Its Oncology Research Program Through Innovative Partnerships
Cystic Fibrosis Genetherapy Development Option Excercise Cystic Fibrosis Genetherapy Development Option Excercise Boehringer Ingelheim and Partners Accelerate BI 3720931 Gene Therapy as long-lasting therapeutic option for patients with cystic fibrosis
Research Beyond Borders Partnering Research Beyond Borders Partnering Our Research Beyond Borders team is looking for emerging science and technology opportunities. Learn more about partnering with us.
Acquisition expands research in cancer immunology Acquisition expands research in cancer immunology Boehringer Ingelheim acquires Abexxa to develop novel cancer therapies by leveraging Abexxa’s unique technology and breakthrough antibody-based drugs.
Europe needs a vibrant research eco-system Europe needs a vibrant research eco-system At this week's EFPIA Days in Brussels, stakeholders will discuss how to re-establish a research-friendly eco-system in Europe.
New cancer research building: Boosting innovation in oncology New cancer research building: Boosting innovation in oncology With our new cancer research building in Vienna, we’ll advance our oncology pipeline and strengthen our commitment to innovation and collaboration.
IL-11 inhibitor antibody clinical development launched IL-11 inhibitor antibody clinical development launched Boehringer Ingelheim has launched clinical development of its first-in-class IL-11 inhibitor antibody as a fibrotic disease treatment
Research Beyond Borders overview Research Beyond Borders overview Learn more about how our Research Beyond Borders team is uncovering new ideas and new science.